Bluebird, Celgene Cancer Therapy Gets Boost From New Study

(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.